Relevance of hydroxyproline excretion to bone metastasis in breast cancer

Relevance of hydroxyproline excretion to bone metastasis in breast cancer

Play all audios:

Loading...

ABSTRACT In 181 consecutive patients with breast cancer, urinary hydroxyproline excretion has been critically evaluated in conjunction with clinical, biochemical, radiological and scintigraphic parameters. The urinary hydroxyproline/creatinine ratio is a sensitive index of the presence of bone metastases. Urinary hydroxyproline excretion is a reliable method of selecting those patients whose elevated serum alkaline phosphatase is secondary to bone disease rather than liver idsease. The estimation of hydroxyproline excretion furthermore gives information on the activity of bone metastasis, and its response to treatment, which cannot be given by radiological or scintigraphic methods. It is doubtful whether urinary hydroxyproline estimation will help to detect bone metastases before they are apparent on scintigrams. When the bone scan is doubtful, as often occurs in older subjects, hydroxyproline excretion has been found to be helpful in classifying the patient. When scintigraphy is not available, an elevation of hydroxyproline excretion, together with an elevation of Ca/cr ratio or alkaline phosphatase activity, may pre-date by several months the radiological demonstration of osseous metastases. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS BONE HEALTH IN NEWLY DIAGNOSED FEMALE BREAST CANCER PATIENTS IN CHINA: A CROSS-SECTIONAL STUDY Article Open access 01 February 2025 BONE MINERAL DENSITY IN WOMEN NEWLY DIAGNOSED WITH BREAST CANCER: A PROSPECTIVE COHORT STUDY Article Open access 17 February 2022 REFERENCE VALUES FOR BONE METABOLISM IN A JAPANESE COHORT SURVEY RANDOMLY SAMPLED FROM A BASIC ELDERLY RESIDENT REGISTRY Article Open access 09 April 2021 Authors * F Gielen View author publications You can also search for this author inPubMed Google Scholar * J Dequeker View author publications You can also search for this author inPubMed Google Scholar * A Drochmans View author publications You can also search for this author inPubMed Google Scholar * J Wildiers View author publications You can also search for this author inPubMed Google Scholar * M Merlevede View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Gielen, F., Dequeker, J., Drochmans, A. _et al._ Relevance of hydroxyproline excretion to bone metastasis in breast cancer. _Br J Cancer_ 34, 279–285 (1976). https://doi.org/10.1038/bjc.1976.163 Download citation * Issue Date: 01 September 1976 * DOI: https://doi.org/10.1038/bjc.1976.163 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

ABSTRACT In 181 consecutive patients with breast cancer, urinary hydroxyproline excretion has been critically evaluated in conjunction with clinical, biochemical, radiological and


scintigraphic parameters. The urinary hydroxyproline/creatinine ratio is a sensitive index of the presence of bone metastases. Urinary hydroxyproline excretion is a reliable method of


selecting those patients whose elevated serum alkaline phosphatase is secondary to bone disease rather than liver idsease. The estimation of hydroxyproline excretion furthermore gives


information on the activity of bone metastasis, and its response to treatment, which cannot be given by radiological or scintigraphic methods. It is doubtful whether urinary hydroxyproline


estimation will help to detect bone metastases before they are apparent on scintigrams. When the bone scan is doubtful, as often occurs in older subjects, hydroxyproline excretion has been


found to be helpful in classifying the patient. When scintigraphy is not available, an elevation of hydroxyproline excretion, together with an elevation of Ca/cr ratio or alkaline


phosphatase activity, may pre-date by several months the radiological demonstration of osseous metastases. Access through your institution Buy or subscribe This is a preview of subscription


content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue


Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL


ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS BONE HEALTH IN NEWLY DIAGNOSED FEMALE


BREAST CANCER PATIENTS IN CHINA: A CROSS-SECTIONAL STUDY Article Open access 01 February 2025 BONE MINERAL DENSITY IN WOMEN NEWLY DIAGNOSED WITH BREAST CANCER: A PROSPECTIVE COHORT STUDY


Article Open access 17 February 2022 REFERENCE VALUES FOR BONE METABOLISM IN A JAPANESE COHORT SURVEY RANDOMLY SAMPLED FROM A BASIC ELDERLY RESIDENT REGISTRY Article Open access 09 April


2021 Authors * F Gielen View author publications You can also search for this author inPubMed Google Scholar * J Dequeker View author publications You can also search for this author


inPubMed Google Scholar * A Drochmans View author publications You can also search for this author inPubMed Google Scholar * J Wildiers View author publications You can also search for this


author inPubMed Google Scholar * M Merlevede View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS


ARTICLE CITE THIS ARTICLE Gielen, F., Dequeker, J., Drochmans, A. _et al._ Relevance of hydroxyproline excretion to bone metastasis in breast cancer. _Br J Cancer_ 34, 279–285 (1976).


https://doi.org/10.1038/bjc.1976.163 Download citation * Issue Date: 01 September 1976 * DOI: https://doi.org/10.1038/bjc.1976.163 SHARE THIS ARTICLE Anyone you share the following link with


will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt


content-sharing initiative